Jonathan Feld, MD

Cancer Focus:
Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Dr. Feld is an assistant member of Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System in Pembroke Pines. He received his MD degree at Albert Einstein College of Medicine of Yeshiva University and completed an Internal Medicine Residency at Beth Israel Deaconess Medical Center, followed by a Hematology and Oncology Fellowship at the Icahn School of Medicine at Mount Sinai, New York. Dr. Felds joins us from Mount Sinai Hospital, Tisch Cancer Institute, where he was appointed as an Assistant Professor of Medicine in the Division of Hematology/Medical Oncology and was a member of the Leukemia/Myelodysplastic Syndrome (MDS) Groups.

Dr. Feld’s clinical interests include malignant hematology, with a particular focus on chronic and acute leukemias, and a special interest in treating patients with myeloid malignancies, especially myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). His research interests are centered around acute and chronic leukemias, with a focus on clinical trials and novel therapeutic development in MDS and AML. Dr Feld has also conducted translational research on understanding how the bone marrow microenvironment, particularly T and NK cells, may impact MDS and AML disease pathogenesis. Dr. Feld grew up in South Florida and is looking forward to returning to his hometown.

Clinical Trial 24218
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial
Condition: Malignant Hematology
Status: Open (affiliates only)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, Kadia TM, Ravandi F, Chien K, Van Hyfte G, Mazumdar M, Saliba A, Mangaonkar A, Lasho T, Al-Kali A, Kremyanskaya M, Feld J, Silverman LR, Komrokji R, Mascarenhas J, Padron E, Garcia-Manero G, Sallman DA, Patnaik MM, Montalban-Bravo G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2025 Jan.39(1):257-260. Pubmedid: 39533069.
• Balev M, Zibara V, Van Hyfte G, Feld J, Kremyanskaya M, Becker M, Keyzner A, Shih AH, Marcellino B, Levavi H, Silverman L, Mascarenhas J, Tremblay D. Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia. Am J Hematol. 2024 Oct.99(10):2026-2028. Pubmedid: 38970273.
• Tharakan S, Feld J, Van Hyfte G, Mascarenhas J, Tremblay D. Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis. Clin Lymphoma Myeloma Leuk. 2024 Oct.24(10):e385-e391.e1. Pubmedid: 39003100.
• Handa S, Farina KA, Becker M, Kelly B, Yu A, Feld J, Tremblay D, Marcellino BK, Salib C, Mascarenhas J, Shih AH. Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights. JCO Precis Oncol. 2024 Jan.8:e2300234. Pubmedid: 38295318. Pmcid: PMC10843369.
• Feld J, Tremblay D, Navada SC, Silverman LR. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. Leuk Lymphoma. 2023 Mar.64(3):525-539. Pubmedid: 36370098.
• Sastow D, Tatarian J, Riazat-Kesh YJRA, Farina K, Becker M, Feld J, Kremyanskaya M, Mascarenhas J, Byrd K, Male HJ, Lin TL, Tremblay D. Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement. Leuk Lymphoma. 2023 Dec.64(12):2002-2007. Pubmedid: 37590099.
• Feld J, Steinberg A, El Jamal SM, Shapira I. Unexpected pancytopenia: Dasatinib induced aplastic anemia in chronic myeloid leukemia. J Oncol Pharm Pract. 2022 Jan.28(1):232-236. Pubmedid: 34152210.
• Cafardi J, Miller C, Terebelo H, Tewell C, Benzaquen S, Park D, Egan P, Lebovic D, Pettit K, Whitman E, Tremblay D, Feld J, Buckley S, Roman-Torres K, Smith J, Craig A, Mascarenhas J. Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2022 Dec.5(12):e2242918. Pubmedid: 36469321. Pmcid: PMC9855296.
• Nathan DI, Feld J, El Jamal SM, Mascarenhas J, Tremblay D. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future. Leuk Res. 2022 Apr.115:106820. Pubmedid: 35279478.
• Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang HH, Anderson-Keightly HM, El Zarif T, Abou Alaiwi S, Rosenbloom TD, Stewart PS, Galsky MD, Choueiri TK, Doroshow DB. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer. 2021 Oct.160:78-83. Pubmedid: 34461400. Pmcid: PMC8284065.
• Tremblay D, Rippel N, Feld J, El Jamal SM, Mascarenhas J. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia. Oncologist. 2021 May.26(5):406-421. Pubmedid: 33792103. Pmcid: PMC8100553.
• Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, Kremyanskaya M, Bar-Natan M, Keyzner A, Marcellino BK, Gabrilove J, Navada SC, Silverman LR, El Jamal SM, Mascarenhas J, Shih AH. Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. Hemasphere. 2021 Apr.5(4):e549. Pubmedid: 33718803. Pmcid: PMC7951133.
• Feld J, Silverman LR, Navada SC. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases. Clin Lymphoma Myeloma Leuk. 2021 Apr.21(4):e415-e422. Pubmedid: 33547022.
• Feld J, Navada SC, Silverman LR. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia. Leuk Res. 2020 Oct.97:106430. Pubmedid: 32763582.
• Tremblay D, Feld J, Dougherty M, Czaplinska T, Sanchez G, Kremyanskaya M, Bar-Natan M, Shih AH, Keyzner A, Mascarenhas J. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm. Leuk Res. 2020 Nov.98:106456. Pubmedid: 33002673.
• Tremblay D, Madero-Marroquin R, Lancman G, Coltoff A, Feld J, Caro J, Sherlock E, Keyzner A, Navada S, Silverman LR, Moshier E, Zubizarreta N, Mascarenhas J. An Opportunity for Hospice Referral in Acute Myeloid Leukemia: Prognostic Significance of Hospitalization Status at Time of Second Cycle of Hypomethylating Agents for Patients Ineligible for Intensive Induction Chemotherapy. J Palliat Med. 2020 Nov.23(11):1424-1425. Pubmedid: 33174777.
• Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, Wang B, Patel V, Jun T, Jandl T, Rahman F, Liu STH, Aberg JA, Bouvier N. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer Med. 2020 Nov.9(22):8571-8578. Pubmedid: 32945149. Pmcid: PMC7537286.
• Feld J, Belasen A, Navada SC. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. Expert Rev Anticancer Ther. 2020 Jun.20(6):465-482. Pubmedid: 32479130.
• Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood. 2020 Jul.136(1):144-147. Pubmedid: 32462179. Pmcid: PMC7332896.
• Feld J, Tremblay D, Thibaud S, Kessler A, Naymagon L. Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2020 Dec.42(6):773-779. Pubmedid: 32790918. Pmcid: PMC7436675.
• Naymagon L, Zubizarreta N, Feld J, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Christian K, Mascarenhas J, Dembitzer F, Moshier E, Tremblay D. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thromb Res. 2020 Dec.196:99-105. Pubmedid: 32853982. Pmcid: PMC7439969.
• Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang HH, Anderson-Keightly HM, Abou Alaiwi S, Rosenbloom TD, Stewart PS, Galsky MD, Choueiri TK, Doroshow DB. Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell. 2020 Dec.38(6):769-770. Pubmedid: 33176161. Pmcid: PMC7609043.
• Feld J, Arnason J, O Apos Brien K, Nahas M. Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. Acta Haematol. 2019 Oct.141(4):222-224. Pubmedid: 30947164.
• Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma AK. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018 Dec.128(12):5479-5488. Pubmedid: 30252677. Pmcid: PMC6264739.
• Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget. 2013 Mar.4(3):397-412. Pubmedid: 23651630. Pmcid: PMC3717303.
• Neary JT, Kang Y, Tran M, Feld J. Traumatic injury activates protein kinase B/Akt in cultured astrocytes: role of extracellular ATP and P2 purinergic receptors. J Neurotrauma. 2005 Apr.22(4):491-500. Pubmedid: 15853465.